Deacetylase inhibitor therapy
US9259452B2 · kind B2 · utility
0Cited by
42References
40Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 6, 2015 |
| Grant date | Feb 16, 2016 |
| Priority date | — |
| Expiry date | Jan 6, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.